普萊柯(603566.SH):擬與關聯方一寵健康投設上海萌邦電子商務
格隆匯 9 月 14日丨普萊柯(603566.SH)公佈,為優化公司產業佈局以及為公司寵物疫苗、藥品業務帶來協同效應,公司擬以自有資金與關聯方一寵(上海)健康科技有限公司(“一寵健康”)共同投資設立上海萌邦電子商務有限公司(“上海萌邦”)(暫定名,以公司登記機關核准的名稱為準),公司此次擬投資金額為人民幣900萬元,股權佔比30%。
擬設立企業上海萌邦主要從事寵物用功能性保健品(非藥品)、食品及用品的研發、生產及銷售、寵物生活服務(非診療)。國內相關產業處於行業發展的早期階段,存在行業監管政策變動、市場競爭加劇等方面的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.